Pfizer (NYSE:PFE) - Page 2

Sangamo Jumps on Newest Pfizer Collaboration

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer Inc. (NYSE: PFE) for ...
Read Full Story »

2018 Bull/Bear Outlook: How All 30 DJIA Stocks Will Take the Market to 26,400 or Higher

It is no secret as 2018 kicks into gear that stocks are in the midst of a raging bull market. In fact, this bull market will turn nine years old ...
Read Full Story »

More and More Short Sellers Raising the Stakes in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Meet the Preliminary Dogs of the Dow for 2018

It is no secret that the bull market's strength heading into 2018 is nearing uncharted territory. Wall Street strategists have recently raised their 2018 stock market expectations after the passage ...
Read Full Story »

Disney, General Electric Hobble DJIA on Wednesday

December 20, 2017: Markets opened higher Wednesday but spent most of the day within inches of the break-even line. Maybe a case of "sell the news" now that the Republican ...
Read Full Story »

Tax Reform Stocking Stuffer: Pfizer Dividend Hike & Much Larger Stock Buyback

It is no secret that investors love stock buyback and dividend announcements. Within reason, companies raising dividends and increasing buybacks are particularly loved. Pfizer Inc. (NYSE: PFE) wants its part ...
Read Full Story »

Intel, Microsoft Dominate DJIA Friday

December 15, 2017: Markets opened higher again Friday and continue to put up gains throughout the day. All three major equities indexes posted new intra-day highs as all sectors traded ...
Read Full Story »

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

Shares of Pfizer Inc. (NYSE: PFE) rose about 1.3% in afterhours trading Thursday after the company announced that the U.S. Food and Drug Administration (FDA) had approved Xeljanz (tofacitinib) for ...
Read Full Story »

Why Cellectis Is Winning Big With Its Pfizer Partnership

Shares of Cellectis S.A. (NASDAQ: CLLS) saw a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer Inc. ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Disney, Apple Pace Dow to Monday Gain

December 11, 2017: Markets opened mixed Monday with the DJIA lagging a bit. By mid-afternoon all three major indexes were trading in the green, even if barely. Tech, telecom, and ...
Read Full Story »

Will Consumers Trust Generic Viagra?

If there is one drug from pharmaceutical giants that may have changed the world in lifestyle, Viagra might be the first one that comes to mind. It has helped millions ...
Read Full Story »

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

With 2017 coming to an end, investors are wondering how they should be investing for 2018 and beyond. At the start of December, the Dow was up just over 20% ...
Read Full Story »

Disney, Intel Sink DJIA on Tuesday

December 5, 2017: Markets opened slightly higher Tuesday but the early gains couldn't hold up. Today's economic data showed a higher-than-expected trade deficit coupled with a lower-than-expected services industry index. ...
Read Full Story »

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

With the market looking ready to continue running to all-time highs despite yesterday's selling, many pundits feel this late stage part of the rally is more people trying to get ...
Read Full Story »